PODD - インスレット (Insulet Corporation) インスレット

 PODDのチャート


 PODDの企業情報

symbol PODD
会社名 Insulet Corp (インスレット)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 インシュレット(Insulet Corporation)はインスリン依存型糖尿病患者用のインスリン注入システムであるOmniPodインスリン管理システム(OmniPodシステム)の開発・製造・販売に従事する会社である。OmniPodシステムは一度に約3日間身体に装着される使い捨てのチューブレスOmniPodデバイス、並びに同社のハンドヘルド・無線パーソナル糖尿病マネージャー(PDM)製品を搭載する。OmniPodシステムはポンプ、チュービングの必要性を排除し、自動カニューレ挿入を提供し、無線で通信し、血糖計を統合する2つの装置を備える。OmniPodシステムは従来のポンプで必要とされる外部配管の必要性を排除する2つの部分からなるデザイン、OmniPodデバイス(Pod)およびPDMである。Podは患者がインスリンを満たし、身体に直接着用する自己粘着性装置である。   インスレットは、米国の医療装置メ―カ―。インスリン依存性糖尿病のために、インスリン注入システム「オムニポッド」を開発、製造、販売する。チュ―ブのない「オムニポッド」は約3日間、身体に装着し、「パ―ソナル糖尿病管理」という携帯の制御装置と無線で交信する。このシステムは、自動カニュ―レ挿入機能を備え、血糖測定器を内蔵している。   Insulet Corporation , headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
本社所在地 600 Technology Park Drive Suite 200 Billerica MA 01821 USA
代表者氏名 Patrick J. Sullivan Patrick J. Sullivan
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 978-600-7000
設立年月日 36708
市場名 NASDAQ National Market System
ipoyear 2007年
従業員数 857人
url www.insulet.com
nasdaq_url https://www.nasdaq.com/symbol/podd
adr_tso
EBITDA EBITDA(百万ドル) 19.92800
終値(lastsale) 92.93
時価総額(marketcap) 5482592325.16
時価総額 時価総額(百万ドル) 5202.946
売上高 売上高(百万ドル) 500.13900
企業価値(EV) 企業価値(EV)(百万ドル) 5480.273
当期純利益 当期純利益(百万ドル) -17.04700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Insulet Corporation revenues increased 17% to $247.8M. Net loss decreased 53% to $8.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other income (expense) net increase from $922K to $3.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.31 to -$0.14.

 PODDのテクニカル分析


 PODDのニュース

   Raymond James maintains Insulet at Outperform with a price target of $350.00  2023/05/05 19:46:36 Investing.com
https://www.investing.com/news/pro/insulet-corp-receives-investment-bank-analyst-rating-update-3074807
   Insulet Reports Better-Than-Expected Q1 Earnings As Omnipod 5 Launch Gains Momentum, Lifts Guidance  2023/05/05 13:16:56 Benzinga
Insulet Corporation (NASDAQ: PODD ) reported Q1 sales of $358.10 million Thursday, beating the consensus of $330.84 million . Total Omnipod revenue came in at $357.6 million, up 32.7% year-over-year. Insulet rolled out its next-generation Omnipod 5 in August 2022. Last month, the company also earned FDA clearance for the Omnipod GO, a basal-only insulin delivery device . The company reported … Full story available on Benzinga.com
   BTIG maintains Insulet at Buy with a price target of $355.00  2023/05/05 11:09:37 Investing.com
https://www.investing.com/news/pro/insulet-corp-receives-investment-bank-analyst-rating-update-3074258
   Insulet Corporation 2023 Q1 - Results - Earnings Call Presentation  2023/05/05 07:16:58 Seeking Alpha
The following slide deck was published by Insulet Corporation in conjunction with their 2023 Q1 earnings call.
   Insulet Corporation (PODD) Q1 2023 Earnings Call Transcript  2023/05/05 01:15:19 Seeking Alpha
Insulet Corporation (NASDAQ:NASDAQ:PODD) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ETCompany ParticipantsDeborah Gordon – President-Investor RelationsJim Hollingshead – President…
   $1000 Invested In Insulet 5 Years Ago Would Be Worth This Much Today  2022/08/23 14:41:04 Benzinga
Insulet (NASDAQ: PODD ) has outperformed the market over the past 5 years by 24.25% on an annualized basis producing an average annual return of 35.42%. Currently, Insulet has a market capitalization of $18.24 billion. Buying $1000 In PODD: If an … Full story available on Benzinga.com
   Cowen Reiterates Outperform on Insulet on Omnipod 5 Label Expansion  2022/08/22 18:00:02 Investing.com
https://www.investing.com/news/pro/cowen-reiterates-outperform-on-insulet-on-omnipod-5-label-expansion-432SI-2877639
   Insulet''s Omnipod 5 insulin pump scores FDA nod for toddlers with Type 1 diabetes  2022/08/22 13:59:57 FierceBiotech
Insulet''s Omnipod 5 insulin pump scores FDA nod for toddlers with Type 1 diabetes apark Mon, 08/22/2022 - 09:59
   PODD stock on watch on FDA nod for Omnipod 5 in young children (NASDAQ:PODD)  2022/08/22 10:35:26 Seeking Alpha
Insulin pump maker Insulet Corporation (PODD) announced Monday that the FDA had greenlighted the company’s Omnipod 5 Automated Insulin Delivery System for use in children aged 2 – 5…
   Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes  2022/08/22 10:00:00 Investor Insulet
Omnipod 5 is the first tubeless AID System cleared in the U.S. for preschool children ACTON, Mass. --(BUSINESS WIRE)--Aug. 22, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today
   Insulet Corporation (PODD) CEO Shacey Petrovic on Q1 2022 Results - Earnings Call Transcript  2022/05/06 21:23:07 Seeking Alpha
Insulet Corporation (NASDAQ:NASDAQ:PODD) Q1 2022 Earnings Conference Call May 05, 2022 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Shacey Petrovic -…
   Insulet -11% after Wells Fargo lowers PT after Q1 earnings  2022/05/06 17:56:21 Seeking Alpha
Insulet (PODD) falls 11% after Wells Fargo analyst cuts PT to $345 from $357.The company''s Q1 earnings topped expectations and announced CEO transition.
   Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is ''Progressing Very Well''  2022/05/06 13:55:52 Benzinga
Insulet Corporation (NASDAQ: PODD ) posted Q1 profits of $27.8 million , or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million, exceeding the guidance range of 13% to 16% in constant currency and the consensus of $288.18 million. “We are off to a great start … Full story available on Benzinga.com
   May 5, 2022 4:30 PM EDT : Q1 2022 Insulet Corporation Earnings Conference Call  2022/05/05 20:30:00 Investor Insulet
The Investor Relations website contains information about Insulet Corporation''s business for stockholders, potential investors, and financial analysts.
   Insulet CEO Shacey Petrovic to step down  2022/05/05 20:26:30 Seeking Alpha
Insulet (PODD) said Thursday Shacey Petrovic will step down from her role as president and CEO for personal reasons, effective Jun. 1.Petrovic will continue to serve on PODD''s board

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 インスレット PODD Insulet Corporation)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)